Old versus new: weighing the evidence between the firstand second-generation antipsychotics

被引:22
|
作者
Davis, JM [1 ]
Chen, N [1 ]
机构
[1] Univ Illinois, Univ Maryland Psychiat Res Ctr, Dept Psychiat, Chicago, IL 60680 USA
关键词
antipsychotics; meta-analysis; efficacy; dose;
D O I
10.1016/j.eurpsy.2004.11.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In our opinion the best guide to prescribing antipsychotics is the clinician's experience with his patients and in particular the patient being treated. If treatment works. stick with it. We feel it is also important for the clinician to consider the evidence front well-controlled double-blind random-assignment studies because in "evidence-based medicine," biases both known and unknown are controlled by blinding, and randomization. The purpose of this paper is to summarize and discuss the evidence on efficacy. Choice of antipsychotic. in our opinion. is probably the most important decision that the clinician makes for the psychotic patient. This involves the choice of drug. its dose. balancing efficacy, side-effects and cost. (C) 2004 Published by Elsevier SAS.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [1] Interactions between antiepileptics and second-generation antipsychotics
    de Leon, Jose
    Santoro, Vincenza
    D'Arrigo, Concetta
    Spina, Edoardo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (03) : 311 - 334
  • [2] Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol
    Goikolea, J. M.
    Colom, F.
    Torres, I.
    Capapey, J.
    Valenti, M.
    Undurraga, J.
    Grande, I.
    Sanchez-Moreno, J.
    Vieta, E.
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 144 (03) : 191 - 198
  • [3] Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review
    Takeuchi, Hiroyoshi
    Thiyanavadivel, Sadhana
    Fervaha, Gagan
    Remington, Gary
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (02) : 274 - 276
  • [4] Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
    Kishimoto, T.
    Agarwal, V.
    Kishi, T.
    Leucht, S.
    Kane, J. M.
    Correll, C. U.
    MOLECULAR PSYCHIATRY, 2013, 18 (01) : 53 - 66
  • [5] Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
    T Kishimoto
    V Agarwal
    T Kishi
    S Leucht
    J M Kane
    C U Correll
    Molecular Psychiatry, 2013, 18 : 53 - 66
  • [6] Second-generation antipsychotics: a therapeutic downturn?
    Lewis, Shon
    PSYCHOLOGICAL MEDICINE, 2009, 39 (10) : 1603 - 1606
  • [7] Diabetes and second-generation (atypical) antipsychotics
    Chabroux, S.
    Haffen, E.
    Penfornis, A.
    ANNALES D ENDOCRINOLOGIE, 2009, 70 (04) : 202 - 210
  • [8] How Quickly Do Physicians Adopt New Drugs? The Case of Second-Generation Antipsychotics
    Huskamp, Haiden A.
    O'Malley, A. James
    Horvitz-Lennon, Marcela
    Taub, Anna Levine
    Berndt, Ernst R.
    Donohue, Julie M.
    PSYCHIATRIC SERVICES, 2013, 64 (04) : 324 - 330
  • [9] Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia
    Buoli, Massimiliano
    Kahn, Rene S.
    Serati, Marta
    Altamura, A. Carlo
    Cahn, Wiepke
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2016, 31 (04) : 325 - 331
  • [10] Second-generation antipsychotics and bone turnover in schizophrenia
    Okita, Kyoji
    Kanahara, Nobuhisa
    Nishimura, Motoi
    Yoshida, Toshihiko
    Yasui-Furukori, Norio
    Niitsu, Tomihisa
    Yoshida, Taisuke
    Ishikawa, Masatomo
    Kimura, Hiroshi
    Nomura, Fumio
    Iyo, Masaomi
    SCHIZOPHRENIA RESEARCH, 2014, 157 (1-3) : 137 - 141